



CLIENT CODE: C000138361 **CLIENT'S NAME AND ADDRESS:**

NEW DELHI 110030 DELHI INDIA 8800465156

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

CIN - U74899PB1995PLC045956 Email: wellness.eastdelhi@srl.in

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

NEW DELHI, 110092 NEW DELHI, INDIA Tel: 9111591115, Fax:

PATIENT NAME: SHIVANGI ATRI PATIENT ID: SHIVF26119028

0028WB00033 ACCESSION NO: AGE: 32 Years SEX: Female ABHA NO:

RECEIVED: 11/02/2023 09:08 13/02/2023 14:26 DRAWN: REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Biological Reference Interval Units Results <u>Final</u>

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

BLOOD COUNTS,EDTA WHOLE BLOOD				
HEMOGLOBIN (HB)	11.5	Low	12.0 - 15.0	g/dL
METHOD: SPECTROPHOTOMETRY				
RED BLOOD CELL (RBC) COUNT	4.05		3.8 - 4.8	mil/µL
METHOD: ELECTRICAL IMPEDANCE				
WHITE BLOOD CELL (WBC) COUNT	8.30		4.0 - 10.0	thou/µL
METHOD: ELECTRICAL IMPEDANCE				
PLATELET COUNT	198		150 - 410	thou/µL
METHOD: ELECTRICAL IMPEDANCE				
RBC AND PLATELET INDICES				
HEMATOCRIT (PCV)	35.7	Low	36.0 - 46.0	%
METHOD : CALCULATED PARAMETER				
MEAN CORPUSCULAR VOLUME (MCV)	88.1		83.0 - 101.0	fL
METHOD : DERIVED/COULTER PRINCIPLE				
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	28.4		27.0 - 32.0	pg
METHOD : CALCULATED PARAMETER				
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD: CALCULATED PARAMETER	32.2		31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW)	14.9	Hiah	11.6 - 14.0	%
METHOD : DERIVED/COULTER PRINCIPLE		•	11.6 1.16	70
MENTZER INDEX	21.8			
METHOD : CALCULATED PARAMETER				
MEAN PLATELET VOLUME (MPV)	11.7	High	6.8 - 10.9	fL
METHOD : DERIVED/COULTER PRINCIPLE				
WBC DIFFERENTIAL COUNT				
NEUTROPHILS	72		40 - 80	%
METHOD: VCS TECHNOLOGY/ MICROSCOPY				
LYMPHOCYTES	18	Low	20 - 40	%
METHOD: VCS TECHNOLOGY/ MICROSCOPY				
MONOCYTES	5		2.0 - 10.0	%
METHOD: VCS TECHNOLOGY/ MICROSCOPY				
EOSINOPHILS	5		1.0 - 6.0	%
METHOD: VCS TECHNOLOGY/ MICROSCOPY				

00

0 - 1



METHOD: VCS TECHNOLOGY/ MICROSCOPY

BASOPHILS

Page 1 Of 20

%





CLIENT CODE: C000138361
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

NEW DELHI, 110092 NEW DELHI, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956 Email : wellness.eastdelhi@srl.in

PATIENT NAME: SHIVANGI ATRI PATIENT ID: SHIVF26119028

ACCESSION NO: **0028WB00033** AGE: 32 Years SEX: Female ABHA NO:

DRAWN: RECEIVED: 11/02/2023 09:08 REPORTED: 13/02/2023 14:26

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results		Biological Reference Interva	l Units
ABSOLUTE NEUTROPHIL COUNT	5.90		2.0 - 7.0	thou/μL
METHOD : CALCULATED PARAMETER ABSOLUTE LYMPHOCYTE COUNT	1.50		1.0 - 3.0	thou/µL
METHOD : CALCULATED PARAMETER ABSOLUTE MONOCYTE COUNT	0.40		0.2 - 1.0	thou/µL
METHOD : CALCULATED PARAMETER	3.73		0.2 2.0	
ABSOLUTE EOSINOPHIL COUNT	0.42		0.02 - 0.50	thou/µL
METHOD: CALCULATED PARAMETER		_		
ABSOLUTE BASOPHIL COUNT METHOD : CALCULATED PARAMETER	0	Low	0.02 - 0.10	thou/µL
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	3.9			
METHOD : CALCULATED PARAMETER				
ERYTHROCYTE SEDIMENTATION RATI	E (ESR),WHOLE			
E.S.R	67	High	< 20	mm at 1 hr
METHOD: MODIFIED WESTERGREN METHOD BY AUTO	DMATED ANALYSER			
GLUCOSE FASTING, FLUORIDE PLASM	A			
FBS (FASTING BLOOD SUGAR)	91		74 - 106	mg/dL
METHOD: HEXOKINASE				
GLYCOSYLATED HEMOGLOBIN(HBA10 BLOOD	C), EDTA WHOLE			
HBA1C METHOD: HPLC	5.4		Non-diabetic Adult < 5.7 Pre-diabetes 5.7 - 6.4 Diabetes diagnosis: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	%
ESTIMATED AVERAGE GLUCOSE(EAG)	108.3		< 116.0	mg/dL
GLUCOSE, POST-PRANDIAL, PLASMA	100.5		. 11010	g, aL
PPBS(POST PRANDIAL BLOOD SUGAR)	91		Non-Diabetes	mg/dL
TI DS(TOST TRANDIAL DECOD SOCIAL)	31		70 - 140	mg/uL
METHOD: HEXOKINASE				
LIPID PROFILE, SERUM				
CHOLESTEROL, TOTAL	225	High	< 200 Desirable 200 - 239 Borderline High >/= 240 High	mg/dL

 ${\tt METHOD}: {\tt CHOLESTEROL} \ {\tt OXIDASE}, \ {\tt ESTERASE}, {\tt PEROXIDASE}$









CLIENT CODE: C000138361 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030

DELHI INDIA 8800465156

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

NEW DELHI, 110092 NEW DELHI, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956 Email: wellness.eastdelhi@srl.in

PATIENT NAME: SHIVANGI ATRI PATIENT ID: SHIVF26119028

0028WB00033 ACCESSION NO: AGE: 32 Years SEX: Female ABHA NO:

REPORTED: RECEIVED: 11/02/2023 09:08 13/02/2023 14:26 DRAWN:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results		Biological Reference Interv	al Units
TRIGLYCERIDES	302	High	< 150 Normal 150 - 199 Borderline High 200 - 499 High >/= 500 Very High	mg/dL
METHOD : ENZYMATIC, END POINT				
HDL CHOLESTEROL	48		< 40 Low >/=60 High	mg/dL
METHOD: DIRECT MEASURE POLYMER-POLYANION			, 3	
CHOLESTEROL LDL	117		< 100 Optimal 100 - 129 Near or above optimal 130 - 159 Borderline High 160 - 189 High >/= 190 Very High	mg/dL
NON HDL CHOLESTEROL	177	High	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL
METHOD: CALCULATED PARAMETER	60.4	11:	B : 11	
VERY LOW DENSITY LIPOPROTEIN	60.4	nign	Desirable value : 10 - 35	mg/dL
CHOL/HDL RATIO	4.7	High	3.3-4.4 Low Risk 4.5-7.0 Average Risk 7.1-11.0 Moderate Risk > 11.0 High Risk	
LDL/HDL RATIO	2.4		0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate >6.0 High Risk	Risk









CLIENT CODE: C000138361
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

NEW DELHI, 110092 NEW DELHI, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956 Email : wellness.eastdelhi@srl.in

PATIENT NAME: SHIVANGI ATRI PATIENT ID: SHIVF26119028

ACCESSION NO: 0028WB00033 AGE: 32 Years SEX: Female ABHA NO:

DRAWN: RECEIVED: 11/02/2023 09:08 REPORTED: 13/02/2023 14:26

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Final Results Biological Reference Interval Units

Interpretation(s)

- 1) Cholesterol levels help assess the patient risk status and to follow the progress of patient under treatment to lower serum cholesterol concentrations.
- 2) Serum Triglyceride (TG) are a type of fat and a major source of energy for the body. Both quantity and composition of the diet impact on plasma triglyceride concentrations. Elevations in TG levels are the result of overproduction and impaired clearance. High TG are associated with increased risk for CAD (Coronary artery disease) in patients with other risk factors, such as low HDL-C, some patient groups with elevated apolipoprotein B concentrations, and patients with forms of LDL that may be particularly atherogenic.
- 3)HDL-C plays a crucial role in the initial step of reverse cholesterol transport, this considered to be the primary atheroprotective function of HDL
- 4) LDL -C plays a key role in causing and influencing the progression of atherosclerosis and, in particular, coronary sclerosis. The majority of cholesterol stored in atherosclerotic plaques originates from LDL, thus LDL-C value is the most powerful clinical predictor.
- 5)Non HDL cholesterol: Non-HDL-C measures the cholesterol content of all atherogenic lipoproteins, including LDL hence it is a better marker of risk in both primary and secondary prevention studies. Non-HDL-C also covers, to some extent, the excess ASCVD risk imparted by the sdLDL, which is significantly more atherogenic than the normal large buoyant particles, an elevated non-HDL-C indirectly suggests greater proportion of the small, dense variety of LDL particles

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category				
A.CAD with > 1 feature of high risk group				
B. CAD with > 1 feature of Very high risk group or recurrent ACS (within 1 year) despite LDL-C				
< or = 50 mg/dl or polyvascular disease				
1. Established ASCVD 2. Diabetes with 2 1	najor risk factors or evidence of end organ damage 3.			
Familial Homozygous Hypercholesterolemi	a			
1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end				
organ damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6.				
Coronary Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid				
plaque				
2 major ASCVD risk factors				
0-1 major ASCVD risk factors				
erosclerotic cardiovascular disease) Risk Fa	ctors			
1. Age > or = 45 years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use				
2. Family history of premature ASCVD 4. High blood pressure				
5. Low HDL				
	B. CAD with > 1 feature of Very high risk g < or = 50 mg/dl or polyvascular disease 1. Established ASCVD 2. Diabetes with 2 r Familial Homozygous Hypercholesterolemia 1. Three major ASCVD risk factors. 2. Dia organ damage. 3. CKD stage 3B or 4. 4. Ll Coronary Artery Calcium - CAC > 300 AU. plaque 2 major ASCVD risk factors 0-1 major ASCVD risk factors erosclerotic cardiovascular disease) Risk Fasin males and > or = 55 years in females			

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)









Units

CLIENT CODE: C000138361 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030

Test Report Status

DELHI INDIA 8800465156 SRL Ltd

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

Biological Reference Interval

NEW DELHI, 110092 NEW DELHI, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956 Email: wellness.eastdelhi@srl.in

PATIENT NAME: SHIVANGI ATRI PATIENT ID: SHIVF26119028

ACCESSION NO: 0028WB00033 AGE: 32 Years SEX: Female ABHA NO:

13/02/2023 14:26 RECEIVED: 11/02/2023 09:08 REPORTED: DRAWN:

Results

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Extreme Risk Group	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
Category A	$\langle OR = 30 \rangle$	$\langle OR = 60 \rangle$		
Extreme Risk Group	<OR = 30	< OR = 60	> 30	>60
Category B				
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

<u>Final</u>

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM





^{*}After an adequate non-pharmacological intervention for at least 3 months.





CLIENT CODE: C000138361 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030

DELHI INDIA 8800465156

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

NEW DELHI, 110092 NEW DELHI, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956 Email: wellness.eastdelhi@srl.in

PATIENT NAME: SHIVANGI ATRI PATIENT ID: SHIVF26119028

0028WB00033 ACCESSION NO: AGE: 32 Years SEX: Female ABHA NO:

REPORTED: RECEIVED: 11/02/2023 09:08 13/02/2023 14:26 DRAWN:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results		Biological Reference In	terval Units
BLOOD UREA NITROGEN (BUN), SERUM				
BLOOD UREA NITROGEN	11		6 - 20	mg/dL
METHOD : UREASE - UV				
CREATININE, SERUM				
CREATININE	0.57		0.50 - 0.90	mg/dL
METHOD : ALKALINE PICRATE-KINETIC				
BUN/CREAT RATIO				
BUN/CREAT RATIO	19.30	High	5.00 - 15.00	
METHOD: CALCULATED PARAMETER				
URIC ACID, SERUM				
URIC ACID	4.6		2.4 - 5.7	mg/dL
METHOD : URICASE, COLORIMETRIC				
TOTAL PROTEIN, SERUM				
TOTAL PROTEIN	6.9		6.6 - 8.7	g/dL
METHOD: BIURET, SERUM BLANK, ENDPOINT				
ALBUMIN, SERUM				
ALBUMIN	4.3		3.97 - 4.94	g/dL
METHOD: BROMOCRESOL GREEN				
GLOBULIN				
GLOBULIN	2.6		2.0 - 4.0 Neonates - Pre Mature: 0.29 - 1.04	g/dL
METHOD: CALCULATED PARAMETER				
ELECTROLYTES (NA/K/CL), SERUM				
SODIUM, SERUM	140		136 - 145	mmol/L
METHOD : ISE INDIRECT				
POTASSIUM, SERUM	4.32		3.5 - 5.1	mmol/L
METHOD : ISE INDIRECT				
CHLORIDE, SERUM	105		98 - 107	mmol/L
METHOD : ISE INDIRECT				









SHIVF26119028

CLIENT CODE: C000138361 **CLIENT'S NAME AND ADDRESS:**

SOUTH WEST DELHI

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI

0028WB00033

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

NEW DELHI, 110092

NEW DELHI, INDIA

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

PATIENT ID:

NEW DELHI 110030 **DELHI INDIA** 8800465156

ACCESSION NO:

Email: wellness.eastdelhi@srl.in

ABHA NO:

PATIENT NAME: SHIVANGI ATRI AGE: 32 Years

RECEIVED: 11/02/2023 09:08 REPORTED: 13/02/2023 14:26 DRAWN:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results Biological Reference Interval Units **Final**

SEX: Female

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake, prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome, osmotic diuresis (e.g., hyperglycemia), alkalosis, familial periodic paralysis, trauma (transient). Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea),diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice,oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration,renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics,NSAIDs, beta-blockers, ACE inhibitors, highdose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences:Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW

METHOD: VISUAL

SLIGHTLY HAZY APPEARANCE

METHOD: VISUAL

CHEMICAL EXAMINATION, URINE

6.0 4.7 - 7.5

METHOD: DOUBLE INDICATOR PRINCIPLE

SPECIFIC GRAVITY <=1.005 1.003 - 1.035

METHOD: PKA CHANGE OF PRETREATED POLYELECTROLYTES

PROTEIN NOT DETECTED NOT DETECTED

METHOD: PROTEIN- ERROR INDICATOR

GLUCOSE NOT DETECTED NOT DETECTED

METHOD: OXIDASE-PEROXIDASE REACTION

KETONES NOT DETECTED NOT DETECTED

METHOD: ACETOACETIC REACTION WITH NITROPRUSSIDE

BLOOD NOT DETECTED NOT DETECTED



Page 7 Of 20





CLIENT CODE: C000138361 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030

DELHI INDIA 8800465156

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

NEW DELHI, 110092 NEW DELHI, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956 Email: wellness.eastdelhi@srl.in

PATIENT NAME: SHIVANGI ATRI PATIENT ID: SHIVF26119028

0028WB00033 ACCESSION NO: AGE: 32 Years SEX: Female ABHA NO:

REPORTED: RECEIVED: 11/02/2023 09:08 13/02/2023 14:26 DRAWN:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results	Biological Reference I	nterval Units
METHOD: PEROXIDASE-LIKE ACTIVITY OF HEMOGLOBIN			
BILIRUBIN	NOT DETECTED	NOT DETECTED	
METHOD : DIAZOTIZATION			
UROBILINOGEN	NORMAL	NORMAL	
METHOD: MODIFIED EHRLICH REACTION			
NITRITE	NOT DETECTED	NOT DETECTED	
METHOD: CONVERTION OF NITRATE TO NITRITE			
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED	
METHOD: ESTERASE HYDROLYSIS ACTIVITY			
MICROSCOPIC EXAMINATION, URINE			
RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
METHOD: MICROSCOPIC EXAMINATION			
PUS CELL (WBC'S)	2-3	0-5	/HPF
METHOD: MICROSCOPIC EXAMINATION			
EPITHELIAL CELLS	10-15	0-5	/HPF
METHOD: MICROSCOPIC EXAMINATION			
CASTS	NOT DETECTED		
METHOD: MICROSCOPIC EXAMINATION			
CRYSTALS	NOT DETECTED		
METHOD: MICROSCOPIC EXAMINATION			
BACTERIA	DETECTED (+)	NOT DETECTED	
METHOD: MICROSCOPIC EXAMINATION			
YEAST	NOT DETECTED	NOT DETECTED	







CLIENT CODE: C000138361
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

NEW DELHI, 110092 NEW DELHI, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956 Email : wellness.eastdelhi@srl.in

PATIENT NAME: SHIVANGI ATRI PATIENT ID: SHIVF26119028

ACCESSION NO: **0028WB00033** AGE: 32 Years SEX: Female ABHA NO:

DRAWN: RECEIVED: 11/02/2023 09:08 REPORTED: 13/02/2023 14:26

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Final Results Biological Reference Interval Units

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
	bladder catheters for profoliged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

THYROID PANEL, SERUM

T3 128.7 80.00 - 200.00 ng/dL

METHOD : ECLIA

T4 9.89 5.10 - 14.10 μg/dL

METHOD : ECLIA









CLIENT CODE: C000138361 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, LADO SARAI, MEHRAULI

8800465156

SOUTH WEST DELHI **NEW DELHI 110030 DELHI INDIA**

Tel: 9111591115, Fax:

NEW DELHI, 110092

NEW DELHI, INDIA

CIN - U74899PB1995PLC045956 Email: wellness.eastdelhi@srl.in

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

3rd Trimester: 0.21 - 3.15

PATIENT NAME: SHIVANGI ATRI PATIENT ID: SHIVF26119028

ACCESSION NO: 0028WB00033 AGE: 32 Years SEX: Female ABHA NO:

RECEIVED: 11/02/2023 09:08 REPORTED: 13/02/2023 14:26 DRAWN:

REFERRING DOCTOR: CLIENT PATIENT ID:

Test Report Status Results Biological Reference Interval Units **Final** TSH (ULTRASENSITIVE) 1.940 Non Pregnant Women μIU/mL 0.27 - 4.20Pregnant Women 1st Trimester: 0.33 - 4.59 2nd Trimester: 0.35 - 4.10

METHOD: ECLIA Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyporthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

PAPANICOLAOU SMEAR



Page 10 Of 20 Scan to View Report





CLIENT CODE: C000138361
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030

DELHI INDIA 8800465156 SRL Ltd

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

NEW DELHI, 110092 NEW DELHI, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956 Email : wellness.eastdelhi@srl.in

PATIENT NAME: SHIVANGI ATRI PATIENT ID: SHIVF26119028

ACCESSION NO: 0028WB00033 AGE: 32 Years SEX: Female ABHA NO:

DRAWN: RECEIVED: 11/02/2023 09:08 REPORTED: 13/02/2023 14:26

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u> Results Biological Reference Interval Units

SPECIMEN TYPE Cytology number C-362-23

Cervical cytological preparation

2 smears examined

REPORTING SYSTEM 2014 Bethesda system

SPECIMEN ADEQUACY Smears are satisfactory for evaluation

MICROSCOPY Endocervical cells/transformation zone component present

Moderate inflammation

INTERPRETATION / RESULT Negative for intraepithelial lesion or malignancy

Comments

Pap smear cytology is a screening test. Corroboration of cytopathologic findings with colposcopic/local examination and ancillary findings is recommended.

PHYSICAL EXAMINATION, STOOL

COLOUR BROWN

METHOD : GUAIAC METHOD

CONSISTENCY SEMI FORMED

METHOD : MANUAL

MUCUS NOT DETECTED NOT DETECTED

METHOD: MANUAL

VISIBLE BLOOD ABSENT ABSENT ABSENT

METHOD: MANUAL

ADULT PARASITE NOT DETECTED

METHOD: CONCENTRATION AND MICROSCOPY

CHEMICAL EXAMINATION, STOOL

STOOL PH 6.5

MICROSCOPIC EXAMINATION, STOOL

PUS CELLS 0-1 /hpf

RED BLOOD CELLS NOT DETECTED NOT DETECTED

 ${\tt METHOD}: {\tt CONCENTRATION} \ {\tt AND} \ {\tt MICROSCOPY}$

CYSTS NOT DETECTED NOT DETECTED

METHOD: CONCENTRATION AND MICROSCOPY

OVA NOT DETECTED

METHOD: CONCENTRATION AND MICROSCOPY

LARVAE NOT DETECTED NOT DETECTED

METHOD: CONCENTRATION AND MICROSCOPY

TROPHOZOITES NOT DETECTED NOT DETECTED

METHOD: CONCENTRATION AND MICROSCOPY

FAT ABSENT





/HPF





SHIVF26119028

CLIENT CODE: C000138361
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd E-368, LGF, Nirman Vihar,Near Nirman Vihar Metro NEW DELHI, 110092

NEW DELHI, 110092 NEW DELHI, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: wellness.eastdelhi@srl.in

PATIENT ID:

PATIENT NAME: SHIVANGI ATRI

ACCESSION NO: 0028WB00033 AGE: 32 Years SEX: Female ABHA NO:

DRAWN: RECEIVED: 11/02/2023 09:08 REPORTED: 13/02/2023 14:26

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u> Results Biological Reference Interval Units

VEGETABLE CELLS ABSENT
CHARCOT LEYDEN CRYSTALS ABSENT

CONCENTRATION METHOD OVA OR CYSTS NOT SEEN









CLIENT CODE: C000138361 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

NEW DELHI, 110092 NEW DELHI, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956 Email: wellness.eastdelhi@srl.in

PATIENT NAME: SHIVANGI ATRI PATIENT ID: SHIVF26119028

ACCESSION NO: 0028WB00033 AGE: 32 Years SEX: Female ABHA NO:

RECEIVED: 11/02/2023 09:08 REPORTED: 13/02/2023 14:26 DRAWN:

REFERRING DOCTOR: CLIENT PATIENT ID:

Test Report Status Results Biological Reference Interval Units **Final**

Interpretation(s)

Stool routine analysis is only a screening test for disorders of gastrointentestinal tract like infection, malabsorption, etc. The following table describes the probable conditions, in which the analytes are present in stool.

PRESENCE OF	CONDITION
Pus cells	Pus in the stool is an indication of infection
Red Blood cells	Parasitic or bacterial infection or an inflammatory bowel condition such as
	ulcerative colitis
Parasites	Infection of the digestive system. Stool examination for ova and parasite detects presence of parasitic infestation of gastrointestinal tract. Various forms of parasite that can be detected include cyst, trophozoite and larvae. One negative result does not rule out the possibility of parasitic infestation. Intermittent shedding of parasites warrants examinations of multiple specimens tested on consecutive days. Stool specimens for parasitic examination should be collected before initiation of antidiarrheal therapy or antiparasitic therapy. This test does not detect presence of opportunistic parasites like Cyclospora, Cryptosporidia and Isospora species. Examination of Ova and Parasite has been carried out by direct and concentration techniques.
Mucus	Mucus is a protective layer that lubricates, protects& reduces damage due to bacteria or viruses.
Charcot-Leyden crystal	Parasitic diseases.
Ova & cyst	Ova & cyst indicate parasitic infestation of intestine.
Frank blood	Bleeding in the rectum or colon.
Occult blood	Occult blood indicates upper GI bleeding.
Macrophages	Macrophages in stool are an indication of infection as they are protective cells.
Epithelial cells	Epithelial cells that normally line the body surface and internal organs show up in stool when there is inflammation or infection.
Fat	Increased fat in stool maybe seen in conditions like diarrhoea or malabsorption.
pH	Normal stool pH is slightly acidic to neutral. Breast-fed babies generally have an acidic stool.

ADDITIONAL STOOL TESTS:

- Stool Culture: This test is done to find cause of GI infection, make decision about best treatment for GI infection & to find out if 1. treatment for GI infection worked.
- Fecal Calprotectin: It is a marker of intestinal inflammation. This test is done to differentiate Inflammatory Bowel Disease (IBD) 2. from Irritable Bowel Syndrome (IBS).
- Fecal Occult Blood Test(FOBT): This test is done to screen for colon cancer & to evaluate possible cause of unexplained anaemia. 3.
- Clostridium Difficile Toxin Assay: This test is strongly recommended in healthcare associated bloody or waterydiarrhoea, due to 4. overuse of broad spectrum antibiotics which alter the normal GI flora.
- Biofire (Film Array) GI PANEL: In patients of Diarrhoea, Dysentry, Rice watery Stool, FDA approved, Biofire Film Array 5. Test, (Real Time Multiplex PCR) is strongly recommended as it identifies organisms, bacteria, fungi, virus, parasite and other opportunistic pathogens, Vibrio cholera infections only in 3 hours. Sensitivity 96% & Specificity 99%.
- Rota Virus Immunoassay: This test is recommended in severe gastroenteritis in infants & children associated with watery 6. diarrhoea, vomitting& abdominal cramps. Adults are also affected. It is highly contagious in nature.









CLIENT CODE: C000138361 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI **NEW DELHI 110030 DELHI INDIA**

8800465156

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

NEW DELHI, 110092 NEW DELHI, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956 Email: wellness.eastdelhi@srl.in

PATIENT NAME: SHIVANGI ATRI PATIENT ID: SHIVF26119028

ACCESSION NO: 0028WB00033 AGE: 32 Years SEX: Female ABHA NO:

RECEIVED: 11/02/2023 09:08 REPORTED: 13/02/2023 14:26 DRAWN:

REFERRING DOCTOR: CLIENT PATIENT ID: **SELF**

Test Report Status Results **Biological Reference Interval** Units **Final**

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

TYPE A ABO GROUP

METHOD: COLUMN AGGLUTINATION TECHOLOGY

POSITIVE RH TYPF

METHOD: COLUMN AGGLUTINATION TECHOLOGY

XRAY-CHEST

»» BOTH THE LUNG FIELDS ARE CLEAR

BOTH THE COSTOPHRENIC AND CARIOPHRENIC ANGELS ARE CLEAR **»**»

BOTH THE HILA ARE NORMAL **»**»

CARDIAC AND AORTIC SHADOWS APPEAR NORMAL BOTH THE DOMES OF THE DIAPHRAM ARE NORMAL

VISUALIZED BONY THORAX IS NORMAL

IMPRESSION NORMAL

TMT OR ECHO

TMT OR ECHO TMT DONE - NORMAL

ECG

ECG SHORT PR INTERVAL

MEDICAL HISTORY

MIGRAINE SINCE 4 YEARS. RELEVANT PRESENT HISTORY RELEVANT PAST HISTORY COVID POSITIVE ON JULY 2022.

RELEVANT PERSONAL HISTORY MARRIED, VEGETARIAN FATHER-HEART DISEASE RELEVANT FAMILY HISTORY **FATHER-DIABETES**

OCCUPATIONAL HISTORY NOT SIGNIFICANT HISTORY OF MEDICATIONS NOT SIGNIFICANT

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS 1.55 mts WEIGHT IN KGS. 61.8 Kgs

BMI 26 BMI & Weight Status as follows: kg/sqmts

Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight

30.0 and Above: Obese

GENERAL EXAMINATION







CLIENT CODE: C000138361 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

NEW DELHI, 110092 NEW DELHI, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956 Email: wellness.eastdelhi@srl.in

PATIENT NAME: SHIVANGI ATRI PATIENT ID: SHIVF26119028

0028WB00033 ACCESSION NO: AGE: 32 Years SEX: Female ABHA NO:

RECEIVED: 11/02/2023 09:08 13/02/2023 14:26 DRAWN: REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

REFERRING DOCTOR: SELF	CLIENT PATIENT ID.			
Test Report Status <u>Final</u>	Results	Biological Reference Interval Units		
MENTAL / EMOTIONAL STATE	NORMAL			
PHYSICAL ATTITUDE	NORMAL			
GENERAL APPEARANCE / NUTRITIONAL STATUS	HEALTHY			
BUILT / SKELETAL FRAMEWORK	AVERAGE			
FACIAL APPEARANCE	NORMAL			
SKIN	NORMAL			
UPPER LIMB	NORMAL			
LOWER LIMB	NORMAL			
NECK	NORMAL			
NECK LYMPHATICS / SALIVARY GLANDS	NOT ENLARGED OR TENDER			
THYROID GLAND	NOT ENLARGED			
CAROTID PULSATION	NORMAL			
TEMPERATURE	NORMAL			
PULSE	76 / MIN REGULAR, ALL BRUIT	PERIPHERAL PULSES WELL FELT, NO CAROTID		
RESPIRATORY RATE	NORMAL			
CARDIOVASCULAR SYSTEM				
BP	114/78	mm/Hg		
PERICARDIUM	NORMAL			
APEX BEAT	NORMAL			
HEART SOUNDS	S1, S2 HEARD NORMALL	Y		
MURMURS	ABSENT			
RESPIRATORY SYSTEM				
SIZE AND SHAPE OF CHEST	NORMAL			
MOVEMENTS OF CHEST	SYMMETRICAL			
BREATH SOUNDS INTENSITY	NORMAL			
BREATH SOUNDS QUALITY	VESICULAR (NORMAL)			

BREATH SOUNDS QUALITY VESICULAR (NORMAL)

ADDED SOUNDS **ABSENT**

PER ABDOMEN

NORMAL APPEARANCE VENOUS PROMINENCE **ABSENT** LIVER NOT PALPABLE **NOT PALPABLE** SPLEEN

CENTRAL NERVOUS SYSTEM









CLIENT CODE: C000138361
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

NEW DELHI, 110092 NEW DELHI, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956 Email : wellness.eastdelhi@srl.in

PATIENT NAME: SHIVANGI ATRI PATIENT ID: SHIVF26119028

ACCESSION NO: **0028WB00033** AGE: 32 Years SEX: Female ABHA NO:

DRAWN: RECEIVED: 11/02/2023 09:08 REPORTED: 13/02/2023 14:26

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status	<u>Final</u>	Results	Biological Reference Interval	Units
HIGHER FUNCTIONS		NORMAL		
CRANIAL NERVES		NORMAL		
CEREBELLAR FUNCTION	NS	NORMAL		
SENSORY SYSTEM		NORMAL		
MOTOR SYSTEM		NORMAL		
REFLEXES		NORMAL		
MUSCULOSKELETAL	SYSTEM			
SPINE		NORMAL		
JOINTS		NORMAL		
BASIC EYE EXAMINA	TION			
CONJUNCTIVA		NORMAL		
EYELIDS		NORMAL		
EYE MOVEMENTS		NORMAL		
CORNEA		NORMAL		
DISTANT VISION RIGH	IT EYE WITH GLASSES	NORMAL		
DISTANT VISION LEFT	EYE WITH GLASSES	NORMAL		
NEAR VISION RIGHT E	YE WITH GLASSES	NORMAL		
NEAR VISION LEFT EYE	WITH GLASSES	NORMAL		
COLOUR VISION		NORMAL		
BASIC ENT EXAMINA	ATION			
EXTERNAL EAR CANAL		NORMAL		
TYMPANIC MEMBRANE		NORMAL		
NOSE		NO ABNORMALITY D	DETECTED	
SINUSES		CLEAR		
THROAT		NO ABNORMALITY D	DETECTED	
TONSILS		NOT ENLARGED		
SUMMARY				
RELEVANT HISTORY		NOT SIGNIFICANT		
RELEVANT GP EXAMIN	ATION FINDINGS	NOT SIGNIFICANT		
RELEVANT LAB INVEST	TGATIONS	HIGH ESR, DYSLIPI	DEMIA, EPITHELIAL CELL DETECTED IN UR	INE
RELEVANT NON PATHO	LOGY DIAGNOSTICS	NO ABNORMALITIES	S DETECTED	

PLEASE CORELATE CLINICALLY



REMARKS / RECOMMENDATIONS







CLIENT CODE: C000138361 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI **NEW DELHI 110030 DELHI INDIA** 8800465156

SRL Ltd

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

NEW DELHI, 110092 NEW DELHI, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956 Email: wellness.eastdelhi@srl.in

PATIENT NAME: SHIVANGI ATRI PATIENT ID: SHIVF26119028

0028WB00033 AGE: 32 Years SEX: Female ACCESSION NO: ABHA NO:

RECEIVED: 11/02/2023 09:08 REPORTED: 13/02/2023 14:26 DRAWN:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results Biological Reference Interval Units **Final**

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive

patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION:

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia
False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLUCOSE FASTING,FLUORIDE PLASMA-**TEST DESCRIPTION**

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in

Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Decreased in

Pancreatic islet cell disease with increased insulin,insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach,fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia),Drugs- insulin, ethanol, propranolol sulfonylureas,tolbutamide, and other oral hypoglycemic agents.

NOTE:

Hypoglycemia is defined as a glucoseof < 50 mg/dL in men and< 40 mg/dL in women.

While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic

index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2.Diagnosing diabetes.
- 3.Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

- 1.eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
 2. eAG gives an evaluation of blood glucose levels for the last couple of months.
- 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

HbA1c Estimation can get affected due to :



Page 17 Of 20 Scan to View Report





CLIENT CODE: C000138361 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

NEW DELHI, 110092 NEW DELHI, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956 Email: wellness.eastdelhi@srl.in

PATIENT NAME: SHIVANGI ATRI PATIENT ID: SHIVF26119028

0028WB00033 AGE: 32 Years SEX: Female ACCESSION NO: ABHA NO:

RECEIVED: 11/02/2023 09:08 REPORTED: 13/02/2023 14:26 DRAWN:

REFERRING DOCTOR: CLIENT PATIENT ID: SELE

Test Report Status Results Biological Reference Interval Units **Final**

I.Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days. II. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

III.Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results. IV.Interference of hemoglobinopathies in HbA1c estimation is seen in

a. Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
b. Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
c. HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-LIVER FUNCTION PROFILE

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that

attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget"""'s disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson"""'s disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.Higher-than-normal levels may be due to:Chronic inflammation or infection,including HIV and hepatitis B or C,Multiple myeloma,Waldenstrom''' disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein.Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc
BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol,

Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

- Blockage in the urinary tract
- Kidney problems, such as kidney damage or failure, infection, or reduced blood flow
 Loss of body fluid (dehydration)
 Muscle problems, such as breakdown of muscle fibers

- Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

- Myasthenia GravisMuscular dystrophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome

Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum.. Protein in the plasma is made up of albumin and globulin

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage),Burns,Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface

of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.









CLIENT CODE: C000138361 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030

DELHI INDIA 8800465156 SRL Ltd

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

NEW DELHI, 110092 NEW DELHI, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956 Email: wellness.eastdelhi@srl.in

PATIENT NAME: SHIVANGI ATRI PATIENT ID: SHIVF26119028

ACCESSION NO: 0028WB00033 AGE: 32 Years SEX: Female ABHA NO:

RECEIVED: 11/02/2023 09:08 REPORTED: 13/02/2023 14:26 DRAWN:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results Biological Reference Interval Units **Final**

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for

The test is performed by both forward as well as reverse grouping methods.

MEDICAL

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.







CLIENT CODE: C000138361
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030

NEW DELHI 110 DELHI INDIA 8800465156 SRL Ltd

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

NEW DELHI, 110092 NEW DELHI, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956 Email : wellness.eastdelhi@srl.in

PATIENT NAME: SHIVANGI ATRI PATIENT ID: SHIVF26119028

ACCESSION NO: 0028WB00033 AGE: 32 Years SEX: Female ABHA NO:

DRAWN: RECEIVED: 11/02/2023 09:08 REPORTED: 13/02/2023 14:26

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u> Results Units

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOWR #SOFFEMPELIED ING

ULTRASOUND ABDOMEN RESULT PENDING

End Of Report
Please visit www.srlworld.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the SRL Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. SRL confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- 8. Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

SRL Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062



